| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 3 Feb 2026 | 19 Jan 2026 |
| Indraprastha Medical Corporation Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/02/2026 inter alia to consider and approve It is hereby informed that a meeting of the Board of Directors of the Company will be held on Tuesday 3rd February 2026 to consider and approve quarterly financial results for the quarter ended 31-12-2025. Pursuant to Regulation 30 and 33 read with Schedule III of the SEBI ( Listing Obligations and Disclosure Requirements) Regulations, 2015 the Board of Directors of the Company at its meeting held on Tuesday, the 3rd February, 2026 i.e. today, considered and approved the following :- 1. Considered and approved unaudited financial results of the Company for the quarter and nine months ended on 31st December 2025. 2. Noted additional affidavit filed by Govt. of NCT of Delhi in the pending Free Patient Matter i.e. SLP (C) No. 29482/2009. 3. Appointed Mr. Harsh Pati Singhania as an additional Director in the category of Non-executive Independent Director for a period of five years. 4. Reappointed Mr. Salil Singhal as an Independent Director for second consecutive term of five years. 5. Reappointed Ms. Vineeta Rai as an Independent Director for second consecutive term of five years. 6. Reappointed Ms. Madhumita Ganguli as Independent Director for second consecutive term of five years. (As Per BSE Announcement Dated on:03.02.2026) | ||
| Board Meeting | 1 Nov 2025 | 17 Oct 2025 |
| Indraprastha Medical Corporation Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2025 inter alia to consider and approve the meeting of board of directors of the company will be held on 1st November 2025 to consider and approve un-audited results for the quarter ended on 30th September 2025. The Board of Directors of the company has at its meeting held on Saturday 1st November 2025, i.e. today, inter alia, consider and approved the un-audited financial results for the quarter ended 30th September 2025, along with the limited review report of the statutory auditor. we are enclosing the same (As per BSE Announcement dated on: 01.11.2025) | ||
| Board Meeting | 6 Aug 2025 | 22 Jul 2025 |
| Indraprastha Medical Corporation Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 06/08/2025 inter alia to consider and approve this is to inform you that a meeting of board of directors is scheduled to be held on Wednesday 6th august 2025 inter- alia to consider and approve of unaudited financial results for the quarter ended 30th June 2025. The board of directors of the company has at its meeting held on Wednesday, 6th August, 2025(i.e., today), inter-alia considered and approved the items as follows: 1. The un-audited financial results for the quarter ended on 30th June, 2025 2. Appointed Mr Sudhir Jalan ( DIN 00111118), as an Independent director. 3. approved convening AGM 4. Fixed the record date. 5. Appointment of cost auditor. 6. Appointment of Sectorial auditor (As Per BSE Announcement Dated on: 06/08/2025) | ||
| Board Meeting | 16 May 2025 | 5 May 2025 |
| Indraprastha Medical Corporation Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 16/05/2025 inter alia to consider and approve This is to hereby inform you that meting of the Board of Directors of the Company will be held on Friday 16th May 2025 Inter Alia:- 1. to consider and approve the audited financial results for the quarter/year ended 31st march 2025; and 2. to consider and recommend dividend if any on equity shares of the Company for the financial year 2024-25. This is to inform you that the Board of Directors of the company has, at its meeting held on Friday, 16th May, 2025 (i.e., Today), inter-alia: 1. Approved the Audited Financial Statements for the year ended 31st March,2025, and Audited Financial Results for the quarter/year ended 31st March, 2025, as recommended by the audit Committee; and, 2. Recommended a dividend @ 45% that is Rs 4.50 per share for the financial year 2024-2025. (As Per BSE Announcement Dated on: 16/05/2025) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2026, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund & Specialized Investment Fund Distributor), PFRDA Reg. No. PoP 20092018
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
